SAT0173 Switching from reference product etanercept to the biosimilar sb4 in a real-life setting: follow-up of 147 patients
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.4391
Abstract: Background The etanercept biosimilar SB4 was introduced in Sweden in early 2016. SB4 has been shown in a randomized controlled trial to be equivalent to its etanercept reference product (ERP) in terms of efficacy and… read more here.
Keywords: sb4; treatment; biosimilar sb4; reference product ... See more keywords
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-214757
Abstract: We read with great interest the recently published results from DANBIO registry on switching from originator etanercept (ETA) to the biosimilar SB4.1 The study includes a really impressive number of patients who underwent mandatory switching… read more here.
Keywords: biosimilar sb4; medical switching; sb4; originator etanercept ... See more keywords